Harvard Bioscience (HBIO) Inventory Average (2011 - 2026)

Harvard Bioscience (HBIO) has 16 years of Inventory Average data on file, last reported at $21.5 million in Q1 2026.

• Quarterly Inventory Average fell 6.62% year-over-year to $21.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.5 million (down 6.62% YoY) and the FY2025 annual result came in at $22.0 million, down 8.15% from the prior year.
• Inventory Average improved to $21.5 million in Q1 2026 per HBIO's latest filing, from $21.2 million in the prior quarter.
• Across five years, Inventory Average topped out at $29.0 million in Q2 2022 and bottomed at $21.2 million in Q4 2025.
• The 5-year median for Inventory Average is $25.3 million (2023), against an average of $25.0 million.
• The widest annual swing landed in 2022, when Inventory Average rose 25.28%; it then dropped 14.2% in 2025.
• Tracing HBIO's Inventory Average over 5 years: stood at $26.3 million in 2022, then decreased by 3.85% to $25.3 million in 2023, then slipped by 2.57% to $24.6 million in 2024, then slipped by 13.86% to $21.2 million in 2025, then advanced by 1.42% to $21.5 million in 2026.
• Per Business Quant, the three latest HBIO Inventory Average figures stand at $21.5 million (Q1 2026), $21.2 million (Q4 2025), and $21.9 million (Q3 2025).

Peer Comparison